Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30432017 | 1.00 | TRPV4 (0.38) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL9340535 | 0.84 | EGLN2 (0.40) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL17651309 | 0.82 | TRPV4 (0.42) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL25202481 | 0.78 | KHK (0.39) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL152108 | 0.78 | EGLN2 (0.43) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL28201225 | 0.78 | TSHR (0.40) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL5952373 | 0.78 | KDM4E (0.38) | TRPV4CYP11B1CYP11B2KDM4EALDH1A1 | |
| SCHEMBL6651902 | 0.77 | TRPV4 (0.48) | TRPV4EGLN2ARCYP11B1CYP11B2 | |
| SCHEMBL237922 | 0.74 | KDM4E (0.35) | TRPV4ARKDM4EALDH1A1CYP1A2 | |
| SCHEMBL30352793 | 0.74 | KDM4E (0.35) | TRPV4ARKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601799-A | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | TRPV4 3176/4885EGLN2 2259/4885AR 2704/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | TRPV4 3176/4885EGLN2 2259/4885AR 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.